Scarica l'app Stockscreener
1.81
4.62%
0.08
Pre-mercato:
1.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$1.73
Aprire:
$1.78
Volume 24 ore:
213.59K
Relative Volume:
0.71
Capitalizzazione di mercato:
$10.96M
Reddito:
$1.38M
Utile/perdita netta:
$-179.05M
Rapporto P/E:
-0.2948
EPS:
-6.14
Flusso di cassa netto:
$-155.03M
1 W Prestazione:
-5.24%
1M Prestazione:
-11.71%
6M Prestazione:
+432.35%
1 anno Prestazione:
+54.70%
Intervallo 1D:
$1.75
$1.83
Intervallo di 1 settimana:
$1.695
$1.95
Portata 52W:
$0.16
$6.83
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Industria
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Confronta BTAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.81 | 10.48M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
Mizuho slashes BioXcel Therapeutics stock price target to $2 from $16 - Investing.com
What is the risk reward ratio of investing in BioXcel Therapeutics Inc. stockTriple-digit wealth increases - jammulinksnews.com
What are BioXcel Therapeutics Inc. company’s key revenue driversCapitalize on market trends with confidence - jammulinksnews.com
What are the technical indicators suggesting about BioXcel Therapeutics Inc.Exceptional profit velocity - jammulinksnews.com
Is it the right time to buy BioXcel Therapeutics Inc. stockBuild a winning investment portfolio - jammulinksnews.com
Does BioXcel Therapeutics Inc. stock perform well during market downturnsDiscover breakthrough stocks before the crowd - jammulinksnews.com
How high can BioXcel Therapeutics Inc. stock price go in 2025Free Discussion Group - Metal.it
What analysts say about BioXcel Therapeutics Inc. stockFree Predictions - PrintWeekIndia
BioXcel Therapeutics Inc. Stock Analysis and ForecastRapid wealth accumulation - PrintWeekIndia
Is BioXcel Therapeutics Inc. a good long term investmentBreakthrough capital growth - PrintWeekIndia
Is BioXcel Therapeutics Inc. stock a good hedge against inflationBreakneck growth rates - jammulinksnews.com
What drives BioXcel Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional
BioXcel stock holds Buy rating at H.C. Wainwright ahead of FDA meeting - Investing.com Canada
BioXcel Therapeutics: Buy Rating Affirmed Amidst Pre-sNDA Submission and Upcoming SERENITY At-Home Trial Results - TipRanks
BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire
Bioxcel Therapeutics' Strategic Move to Expand IGALMI for At-Home Use: Assessing the Market Opportunity and Regulatory Pathway for First-in-Class Agitation Treatment in Outpatient Mental Health - AInvest
BioXcel schedules FDA meeting for IGALMI outpatient use expansion - Investing.com
BioXcel schedules FDA meeting for IGALMI outpatient use expansion By Investing.com - Investing.com Nigeria
BTAI files pre-sNDA to expand IGALMI label for home use | BTAI SEC FilingForm 8-K - Stock Titan
Bioxcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package In Support Of Potential Label Expansion For Igalmi - TradingView
First-Ever At-Home Agitation Drug: FDA to Review IGALMI for 23M Patient Market Opportunity - Stock Titan
why bioxcel therapeutics inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
What makes BioXcel Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets, Price Target Unchanged at $66.00 - AInvest
BTAI: BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets | BTAI Stock News - GuruFocus
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):